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 Abstract 
Gamma-amino butyric acid (GABA), the major inhibitory neurotransmitter in the mammalian 
central nervous system, plays a key role in the regulation of neuronal transmission throughout 
the brain, affecting numerous physiological and psychological processes. Changes in GABA 
levels provoke disbalance between excitatory and inhibitory signals, and are involved in the 
development of numerous neuropsychiatric disorders. GABA exerts its effects via ionotropic 
(GABAA) and metabotropic (GABAB) receptors. Both types of receptors are targeted by many 
clinically important drugs that affect GABAergic function and are widely used in the 
treatment of anxiety disorder, epilepsy, insomnia, spasticity, aggressive behaviour, and other 
pathophysiological conditions and diseases. Of particular importance are drugs that modulate 
GABAA receptor complex, such as benzodiazepines, barbiturates, neuroactive steroids, 
intravenous and inhalational anesthetics, and ethanol. Molecular interactions and subsequent 
pharmacological effects induced by drugs acting at GABAA receptors are extremely complex 
due to structural heterogeneity of GABAA receptors and existence of numerous allosterically 
interconnected binding sites and various chemically distinct ligands that are able to bound to 
them. There is a growing interest in the development and application of subtype-selective 
drugs that will achieve specific therapeutic benefits without undesirable side effects. The aim 
of this review is to briefly summarize the key pharmacological properties of GABA receptors, 
and to present selected novel findings with the potential to open new perspectives in the 
development of more effective therapeutic strategies. 
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Introduction to GABA receptor diversity and pharmacological complexity 
As the principal mediator of inhibitory synaptic transmission in the mammalian brain, 
GABA exerts its effects and shapes behaviour via two different types of GABA receptors. 
While fast ionotropic GABAA receptors belong to the family of ligand gated ion channels, 
metabotropic GABAB receptors are receptors with seven transmembrane domains coupled to 
G-proteins. Activation of GABA receptors by GABA induces membrane hyperpolarization, 
reduces the frequency of the generation of action potentials, and results in inhibition. Mainly 
local-circuit interneurons that constitute 15-20% of all cortical neurons predominantly use 
GABA as the neurotransmitter [1-3]. 
Most of its effects GABA exerts via GABAA receptors. GABAA receptors may be 
embedded in postsynaptic membrane where they mediate transient and fast synaptic inhibition 
that occurs in milliseconds, or may be located at the extrasynaptic places where respond to 
ambient concentrations of GABA and mediate long-term inhibition. In fast synaptic 
inhibition, GABA released from the presynaptic membrane terminals rapidly diffuses across 
the synaptic cleft and binds to binding sites at postsynaptic GABAA receptors. Following 
binding, these receptors undergo a rapid conformational change that opens integral chloride 
channel and permit the flow of chloride ions down their chemical gradient, across the 
postsynaptic membrane. This ensures propagation of neurotransmission and represents basis 
of neural communication [4,5]. 
In contrast to GABA that directly activates and opens ion channels, some drugs, such 
as competitive antagonist bicuculline, selectively block GABAA receptors and prevent 
inhibitory action of GABA. Muscimol, the principal psychoactive constituent of the 
mushroom Amanita muscaria, also acts as a potent, selective agonist of GABAA receptors. A 
variety of clinically important drugs, including anticonvulsants, anxiolytics, general 
anesthetics, barbiturates, ethanol and neuroactive steroids, as well as drugs important as 
research tool such as convulsive picrotoxin, allosterically modulate GABA-induced activation 
of GABAA receptors by acting on distinct binding sites on the receptor and modulate GABA 
action [5,6]. These drug interactions, together with structural diversity of GABAA receptors, 
shape the complex nature of GABAA receptor pharmacology, although simultaneously offer a 
great opportunity for the design of novel and more selective compounds for improved 
therapeutic applications [7]. Unfortunately, severe problems are related to the long-term use 
of drugs acting at GABAA receptors, including loss of efficacy, and development of tolerance 
and dependence that largely limit the time window of their desirable therapeutic benefits [4,8-
11]. 
GABA also achieves inhibitory effects by acting at G-protein-coupled metabotropic 
GABAB receptors. The slow, longer-lasting inhibition of GABAB receptors is mediated by 
indirect gating of either potassium or calcium channels via second messengers. Characteristic 
agonists of GABAB are the GABA analog baclofen and 3-aminopropylphosponous acid (3-
APPA; CGP27492), while saclofen, phaclofen and 2-hydroxysaclofen act as antagonists of 
GABAB receptors [12]. 
Old nomenclature also included GABAC receptors that are expressed predominantly in 
retina. However, International Union of Basic and Clinical Pharmacology has recommended 
that GABAC receptors should be assumed as one of the many isoforms of GABAA receptors 
[5].  
 
GABAA receptors and their subunits 
 
Ubiquitously expressed GABAA receptors are the major receptors of inhibitory 
neurotransmission across the central nervous system (CNS) that play a major role in virtually 
all brain physiological functions. GABAA receptors are heteropentameric ligand-gated 
proteins that form a channel specific for chloride ions as an integral part. GABAA receptors 
are members of the Cys-loop ligand-gated ion channel superfamily due to the presence of a 
disulphide-bridged loop in the extracellular domain. They share structural and functional 
homology with other members of the family. In addition to GABAA receptors, the main 
pentameric receptors within the Cys-loop superfamily are nicotinic acetylcholine (nACh), 5-
hydroxytryptamine type 3 (5HT3) and glycine receptors [13,14].  
GABAA receptors are assembled from an impressive repertoire of different 
homologous subunits that are encoded from the pool of 19 different genes. Six α (α1-6), three β 
(β1-3), three γ (γ1-3), δ, ε, , π and three ρ (ρ1-3) subunits have been identified by molecular 
cloning techniques [6,14-16]. In some cells expression of more than eight different isoforms 
has been demonstrated [5]. Throughout the CNS some subunits are broadly expressed, while 
others exhibit more restricted expression profile [17,18]. For example, the most abundant α1 
subunit is expressed almost ubiquitously in the brain, α5 is highly expressed in the 
hippocampus, α6 subunit is expressed only in granule cells of the cerebellum, while ρ-
subunits, the major molecular components of the formerly called GABAC receptors, are 
expressed mainly in the retina [19-22]. Expression of β2 subunit strongly correlates with that 
of α1, while expression pattern of β3 subunit resembles to that of α2. Isoform γ2 is the most 
widely distributed isoform of γ subunit [17].  
GABAA receptor subtypes composed of different subunits represent distinct receptor 
populations that exhibit unique functional and pharmacological properties, and are 
differentially regulated at the transcriptional, post-transcriptional and translational levels [23]. 
GABAA receptor subtypes are expressed in a specific spatio-temporal pattern in the 
developing and adult CNS. Some combinations of subunits, such as α1β2γ2, the most 
prevalent adult isoform, are broadly distributed in different brain areas, while the expression 
of some other subtypes of GABAA receptors is restricted to certain regions [24].  
Mature subunits share a common topological organization, and have approximately 
450 amino acid residues in length. Subunits consist of a large extracellular N-terminal domain 
that contains already mentioned Cys loop, followed by four transmembrane domains (TM1-
TM4), and a short extracellular C-terminal domain. TM2 domains of all five subunits line the 
lumen of ion channel. There is a large phosphorytable intracellular loop between TM3 and 
TM4 domains of each subunit that participates in protein-protein interactions and plays an 
important role in the regulation of GABAA receptor function. Some of the intracellular 
proteins that interact with GABAA receptors are GABAA receptor associated protein 
(GABARAP), Golgi-specific DHHC zinc finger protein (GODZ) phospholipase C-related, 
catalytically inactive proteins PRIP-1 and PRIP-2, Plic-1, radixin, GABAA receptors 
interacting factor-1 (GRIF-1), and brefeldin A-inhibited GDP/GTP exchange factor 2 (BIG2). 
These proteins interact with particular subunits at GABAA receptor complex and modulate 
broad spectrum of GABAA receptors activities, such as trafficking enhancement, surface 
stabilization, receptor internalization, anchoring of receptors in the cytoskeleton, and 
regulation of modification of GABAA receptors [5,25]. 
Chromosomal mapping techniques revealed that the majority of genes coding for the 
subunits of GABAA receptors are localized into four clusters on chromosomes 4, 5, 15 and X 
in the human genome, and within these clusters genes have conserved transcriptional 
orientation [26]. Additional diversity of receptor structure is accomplished by alternative 
splicing of some of the subunit mRNAs and by RNA editing that might affect kinetics, 
subunit assembly and cell-surface expression of GABAA receptors [27]. For example, the γ2 
subunit appears in three alternatively spliced variants termed γ2L, γ2S and γ2XL [28], 
although physiological and pharmacological relevance of this diversity is still not completely 
resolved. Nova, a neuron-specific RNA binding protein, regulates alternative splicing of γ2 
subunit by acting on an intronic splicing enhancer which lies far downstream of the regulated 
exon, and general dysregulation of Nova's splicing enhancer function may underlie the 
neurologic defects seen in patients with Nova's absence [29]. 
Only a limited number of mutations have been found in GABAA receptor subunit 
genes that are specific for different diseases. For example, point mutations in the α1 and γ2 
subunits are found in patients with genetic epilepsies, while single nucleotide polymorphisms 
(SNPs) in the gene encoding the α2 subunit are involved in alcohol dependence and illicit 
drug dependence. The gene encoding the β1 subunit also has been linked to alcohol 
dependence and to bipolar disorder. The genes encoding the α1, α6, β2 and π subunits have 
been linked to schizophrenia [4]. 
 
Subunit composition determines pharmacological effects 
 
It is still not resolved which subunits assemble together to form different isoforms of 
GABAA receptors that really exist in nature [14]. Numerous expression studies using 
recombinant receptors indicated that receptors composed of α, β, and γ subunits form GABAA 
receptors with a pharmacological profile that mimic properties of the majority of native 
receptors. Despite the fact that the immense number of different pentameric combinations can 
be assembled from the pool of native protein subunits, it seems that the prevalent form of 
native GABAA receptors is the combination of two α, two β and a single γ, δ or ε subunit 
[30,31]. As mentioned before, isoform α1β2γ2 is considered as the most prevalent subtype of 
adult GABAA receptors, with γ2β2α1β2α1 counter-clockwise arrangement surrounding 
central ion pore when viewed from the synaptic cleft [32]. It is estimated that approximately 
60% of all GABAA receptors have the subunit composition α1β2γ2, approximately 15–20% 
have the α2β3γ2 combination, approximately 10–15% have the α3βnγ2 combination, 
approximately 5% have the α4βnγ or α4βnδ combination, less than 5% have the α5β2γ2 
combination and, likewise, less than 5% have the α6β2/3γ2 combination [4]. Furthermore, it 
is possible for GABAA receptors to contain two different  subunits. Thus, α16βxγ2 and 
α16βx receptors have been found in the cerebellum [33].  
Composition and arrangement of GABAA receptors subunits shapes the synaptic 
response to GABA, as well as electrophysiological, functional and pharmacological properties 
of GABAA receptors, including potency and efficacy of different drugs to exert their effects 
[6,34,35]. For example, Zezula et al. [36] systematically investigated properties of 
recombinant GABAA receptors formed after transfection of human embryonic kidney (HEK) 
293 cells with α1-, β3-, or γ2-subunits, or with various combinations of these subunits. From 
all possible subunit combinations, high affinity binding sites for GABA were formed in cells 
transfected with α1β3- or α1β3γ2-subunits only. Binding of benzodiazepines were induced in 
cells after transfection with α1γ2- or α1β3γ2 subunits, whereas binding sites for convulsant 
[35S]t-butylbicyclophosphorothionate (TBPS) were found in cells transfected with β3-, β3γ2-, 
α1β3-, or α1β3γ2-subunits. Binding of [35S]TBPS was inhibited by pentobarbital 
(barbiturate), alphaxalone (anesthetic neuroactive steroid) and propofol (anesthetic) with a 
potency which differed in cells transfected with β3-, β3γ2-, α1β3-, or α1β3γ2-subunits, 
demonstrating that receptors with different subunit composition exhibit distinct 
pharmacological properties. 
 
Tonic and phasic inhibition by GABAA receptors 
 
Some subunits, such as  subunits, are placed only at extrasynaptic places where 
GABAA receptors are activated by low ambient GABA concentrations present in the 
extracellular fluid, and mediate a so-called tonic inhibition that is relatively non-desensitizing. 
Isoforms containing γ subunit are expressed predominantly at synapses and mediate rapidly 
desensitizing phasic GABAergic neurotransmission. Synaptic GABAA receptors are activated 
transiently after the release of GABA from presynaptic vesicles, while extrasynaptic GABAA 
receptors are in general activated continuously, controlling neuronal excitability and the 
strength of synaptic transmission [37-41]. 
Tonic and phasic conductances underlie different physiological and behavioural 
processes [4]. Receptors containing δ subunit regulate numerous behavioural functions, 
including memory, nociception and anxiety, and may modulate neurogenesis. Taking into 
account that they are highly responsive to sedative-hypnotic and sleep-promoting drugs, 
general anesthetics, alcohol and neuroactive steroids, they are considered as potential 
therapeutic targets for the treatment of memory impairment, insomnia, mood disorders, pain, 
and post-stroke recovery [39,41-44].  
Furthermore, extrasynaptic GABAA receptors with δ subunit exhibit a pronounced 
variability in expression levels under different physiological and pathophysiological 
conditions that might reshape behaviour and change neuronal susceptibility to different drugs 
[41]. Modulation of tonic inhibition might be of clinical relevance as extrasynaptic GABAA 
receptors may diminish seizure susceptibility and states of anxiety during the estrous cycle. In 
particular, in late diestrus in mice (high-progesteron phase), increased expression of δ-
containing receptors increases tonic inhibition, suggesting that consequent reduction of 
neuronal excitability might be beneficial in women with catamenial epilepsy and premenstrual 
dysphoric disorder [45]. The large increase in progesterone-derived neurosteroids during 
pregnancy, and their sharp decline at parturition, may also have considerable effects on 
GABAA receptors during pregnancy and postpartum. Both tonic and phasic inhibition 
decrease in pregnant mice due to down-regulation of  and 2 subunits, and are rebound 
immediately after delivery. Mice which do not exhibit -subunit regulation throughout 
pregnancy show depression-like and abnormal maternal behaviours [46]. On the other hand, 
expression of GABAA receptors containing δ subunit is diminished in depression and 
schizophrenia [47,48]. 
 
Endogenous ligands of GABAA receptors 
 
In addition to GABA, neurosteroids are the most important endogenous ligands of 
GABAA receptors. Certain neurosteroids potently and specifically enhance function of 
GABAA receptors, and consequently exert anxiolytic, analgesic, anticonvulsant, sedative, 
hypnotic and anesthetic properties, and contribute to behavioural effects of psychoactive 
substances [49]. In the CNS, steroids can be synthesized de novo from cholesterol, during 
stress, pregnancy and after ethanol consumption, and these steroids are called neurosteroids, 
or can be converted from steroid precursors from periphery [50-52]. De novo synthesized 
neuroactive steroids locally modify neuronal activity in a paracrine manner, and can influence 
mood and behaviour in various physiological and pathophysiological conditions. GABA-
modulatory actions of the pregnane steroids are highly selective, with their actions being brain 
region- and neuron-dependent. Furthermore, the sensitivity of GABAA receptors to 
neurosteroids is not static but can dynamically change. The molecular mechanisms 
determining this neuronal specificity include different GABAA receptor isoforms, protein 
phosphorylation and local steroid metabolism and synthesis [53,54]. 
Relatively recently, it has been discovered that endocannabinoid 2-arachidonoyl 
glycerol (2-AG) potentiates GABAA receptors at low concentrations of GABA, specifically in 
receptors containing β2 subunit [55]. 2-AG allosterically potentiates GABAA receptors via a 
binding site located in transmembrane segment TM4 of the β2 subunit GABAA receptors [56]. 
The discovery of a direct action of the 2-AG on the β2-containing GABAA receptors offers 
the potential for selective pharmacological intervention that would reduce motility and 
possibly affect sedation and state of anxiety [56]. Furthermore, it is shown that 2-AG acts 
synergistically with the neurosteroid tetrahydrodeoxycorticosterone (THDOC; 3α,21-
dihydroxy-5α-pregnan-20-one) and modulates extrasynaptic receptors that respond to 
neurosteroids [55]. 
 
 
Modulation of GABAA receptors by pharmacological agents 
 
GABAA receptors are targeted by many clinically important drugs. Namely, besides 
binding site(s) for GABA, GABAA receptors possess binding sites for a variety of clinically 
important substances, such as benzodiazepines and benzodiazepine-site ligands, barbiturates, 
intravenous and volatile anesthetics, ethanol and neuroactive steroids, all of which achieve at 
least some of their pharmacological effects after binding to GABAA receptor complex 
[6,17,57]. These drugs modulate effects of GABA and affect GABAergic transmission, 
exerting a wide spectrum of pharmacological effects and inducing numerous conformational 
states of GABAA receptors.  
Diverse approaches have been applied in last years to more precisely identify various 
binding sites on GABAA receptor complex, as this knowledge is prerequisite for the design of 
subtype specific, selective drugs of clinical relevance. Study performed on the comparative 
models of the extracellular and transmembrane domains of GABAA receptors in the agonist-
free state has revealed that a loose packing of these domains results in a large amount of 
solvent-accessible space, probably offering a potential explanation for such complex 
pharmacology and great flexibility of GABAA receptors [58]. 
Drugs acting at benzodiazepine binding sites can only modulate GABAA receptors, 
while barbiturates, neuroactive steroids and anesthetics at higher concentrations are able to 
directly activate GABAA receptors in the absence of GABA [31,59-63]. Binding sites for all 
of these drugs are allosterically coupled. Therefore, drug that fits or binds to any of these 
multiple binding pockets induces conformational changes of the receptor complex and 
modulates GABA-elicited response [64,65]. For some of these multiple binding sites ligands 
have been identified, whereas for others sites, ligands are unknown. Similarly, the sites of 
action of large number of compounds that allosterically modulate GABAA receptors are still 
not identified [66].  
Increased activity of GABAA receptor activity leads to anxiolysis, ataxia, 
myorelaxation, sedation, hypnosis, anesthesia and anterograde amnesia, whereas decrease in 
GABAA receptor activity leads to increased vigilance, memory enhancement, anxiety and 
seizures [6,67]. GABAA receptors are therefore widely used in the treatment of anxiety 
disorders, insomnia, epilepsy, restlessness, and aggressive behaviours [17,68]. Recently, 
Rudolph and Möhler [69] gave comprehensive overview of the role of GABAA receptor 
subtypes on cognitive and emotional behaviour, particularly to cognitive dysfunction and 
Down syndrome, anxiety disorders, depression, schizophrenia, and autism. They highlighted 
that a partial inverse agonist acting at the α5-subunit-containing GABAA receptors is in a 
clinical trial in individuals with Down syndrome. Substances that selectively reduce function 
of α5-containing GABAA receptors are considered as potential cognition enhancers for 
Alzheimer's syndrome and other dementia, consistent with genetic studies implicating 
GABAA receptors in learning performances [70]. With regard to anxiety disorders, 
nonsedative anxiolytics based on the modulation of α2- and α3-subunit-containing GABAA 
receptors have been established in clinical proof-of-concept trials. Furthermore, Rudolph and 
Möhler [69] emphasized the GABA hypothesis of depression and new options for 
antidepressant drug development. They also pointed out that cognitive symptoms in 
schizophrenia are attributed to a cortical GABAergic deficit, and that dysfunctional 
GABAergic inhibition contributes to the pathophysiology of autism spectrum disorders. 
Furthermore, the properties of GABAA receptors specific to interneurons may differ 
significantly from those found on projecting neurons, offering the possibility of developing 
interneuron-specific drugs that is of great therapeutic interest as more and more neurological 
and psychiatric disorders are linked to malfunction or deficits of interneurons [3]. Cells of 
glial origin also express GABAA receptor subunit isoforms and form functional ion channels 
that are modulated by classical GABAA receptor drugs, including diazepam and anesthetics 
etomidate and propofol [71]. 
 
 
Effects of GABA and GABA agonists at GABAA receptor 
 
Besides GABA, other compounds also act at GABA recognition sites. Muscimol, 
4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridine-3-ol (THIP, a bicyclic muscimol analog) and 
isoguvacine are structural analogs of GABA, and have direct GABA mimetic effects, while 
alkaloid bicuculline competitively antagonises effects of GABA at GABA binding sites. 
Muscimol has been widely used as a valuable tool to study pharmacology of GABAA 
receptors, and was the lead compound in the development of a range of GABAergic agents 
[72-74]. Behavioural effects of muscimol and THIP are preferentially mediated via high-
affinity agonist binding sites at extrasynaptic receptors containing 4 and  subunits. For 
THIP at high concentrations, the superagonistic behaviour on 43 receptors is achieved 
due to its ability to increase the duration of longer channel openings and their frequency, 
resulting in longer burst durations, while muscimol-related moderate superagonist behaviour 
is caused by reduced receptor desensitisation [75]. The ability to specifically increase the 
efficacy of extrasynaptic receptor activation by selected exogenous agonists might have 
important therapeutic implications, particularly under circumstances when synaptic inhibition 
is compromised, enabling manipulation of different components of inhibitory circuits [75-77]. 
Furthermore, it was found that chronic activation of GABAA receptors by muscimol may 
exert neuroprotective effects against A-induced apoptotic neuronal death [78].  
Radioligand binding studies indicated that GABA and GABA agonists stimulate 
binding of benzodiazepine agonists, and inhibit binding of inverse agonists at benzodiazepine 
binding site. Vice versa, GABA binding is stimulated by benzodiazepines, barbiturates, 
neuroactive steroids and anesthetics. Picrotoxin and other convulsants allosterically inhibit 
binding of GABA at GABAA receptors [79-83]. Studies with [
3H]muscimol and [3H]GABA 
have revealed two kinds of agonist binding sites on the GABAA receptor that differ in affinity. 
Biochemical and pharmacological experiments have suggested that high- and low-affinity 
sites might be interchangeable conformational variants of the same receptor complex. In most 
studies, functional responses to GABA have been observed only at micromolar 
concentrations, while nanomolar concentrations are needed to occupy the high-affinity 
binding sites. Hence, it is possible that the high-affinity sites represent a desensitized form of 
GABAA receptors or otherwise non-functional binding sites [76,84]. 
The binding site for GABA at GABAA receptor is located at the extracellular interface 
between the α and the β subunit, and a number of amino acids residues in the binding pocket 
have been identified that are important for pharmacological activity, subtype selectivity, 
assembly, trafficking and surface expression [84-87]. At the major, and the best characterized 
subtype of GABAA receptor that is assembled from ,  and  subunits, there are two binding 
sites for GABA. When two molecules of GABA bind to receptor complex, the receptor 
channel opens, and chloride ions rush into the postsynaptic neuron. However, as one pair of 
these otherwise identical subunits is flanked by  and  (site 1) and the other by  and  (site 
2), different environments affect the binding sites. In 122 receptors, site 2 has an 
approximately threefold higher affinity for GABA than site 1, whereas muscimol and 
bicuculline show some preference for site 1. Opening of the chloride channel also occurs for 
receptors occupied with a single agonist molecule but is promoted approximately 60-fold in 
those occupied by two agonists [88]. After occupancy of GABA binding sites, the large 
portion of the receptor undergo conformational changes that trap agonist inside the binding 
pocket, a deep narrowing cleft that probably may constrict during channel gating [64].  
The potency of GABA in opening chloride channels is determined by subunit 
composition. For example, in one study aimed to characterize the potency of GABA at human 
recombinant δ-containing extrasynaptic GABAA receptors expressed in Xenopus oocytes, it is 
found that α4/δ-containing receptors display high sensitivity to GABA, with mid-nanomolar 
concentrations activating α4β1δ and α4β3δ receptors. In the majority of oocytes expressing 
α4β3δ subtypes, GABA produced a biphasic concentration-response curve, and activated the 
receptor with low and high concentrations, while at α4β2δ receptors, GABA exerted low 
micromolar activity. An analysis of 10 point mutations in the large N-terminal extracellular 
domains in α4β3δ receptors shows that GABA interacts with amino acids different to those 
reported for α1β2γ2 GABAA receptors suggesting that GABA may have different binding 
modes for extrasynaptic δ-containing GABAA receptors compared to their synaptic 
counterparts [89].   
 
 
Effects of drugs acting at benzodiazepine binding sites at GABAA receptor 
 
Due to their pharmacological and clinical relevance, benzodiazepines have attracted 
much attention as allosteric modulators of GABAA receptors. Various ligands acting at 
benzodiazepine binding site can enhance (positive modulators or agonists) or reduce (negative 
modulators or inverse agonists) the actions of GABA on GABAergic transmission with a 
different range of efficacy (from full to partial). Antagonists are devoid of intrinsic activity, 
but can inhibit effects of both positive and negative modulators [6].  
Benzodiazepines and other substances acting at the benzodiazepine binding site are the 
most commonly prescribed drugs in therapeutic use due to their desirable anxiolytic, 
myorelaxant, sedative/hypnotic and anticonvulsant effects. Classical benzodiazepines, such as 
diazepam and flunitrazepam, do not open channel directly, but allosterically potentiate 
activation of GABAA receptor containing either α1, -2, -3 or -5 subunits. This means that after 
their binding, conformational changes at the receptor confer to increased affinity for channel 
gating by GABA at both agonist sites. Accordingly, in electrophysiological recordings 
classical benzodiazepines do not affect the maximal current amplitude, but GABA 
concentrations required for channel opening are shifted to lower values. In contrast to them, 
negative allosteric modulators shift GABA concentration curve to the right [5].  
The subunit composition of the GABAA receptor complex largely determines 
pharmacological properties at benzodiazepine binding site. In fact, pharmacological profile is 
predominantly determined by α and γ subunits isoforms. It has been shown that different 
receptor conformations, in particular 16, 61, 11 and 66, have their 
own pharmacological signature and that diazepam efficacy is determined exclusively by the 
- subunit neighbouring the 2-subunit [35]. The most applied concept is that the α1βxγ2-
receptors, called type I BZ receptors, preferentially bind full benzodiazepine agonists with 
high affinity, while α2/3/5βxγ2-receptors, classified as type II BZ receptors, have 
approximately 10-fold lower affinity for benzodiazepine agonists [24,81]. Sedative, 
anterograde amnesic and partly anticonvulsant properties are attributed to α1-containing 
receptors, while the presence of α2 and/or α3 subunits determines anxiolytic and myorelaxant 
activity of benzodiazepines [90-92]. This means that compound that selectively modulates 
receptors with α2 and/or α3 subunits, but not α1-containing receptors, would be a non-
sedating anxiolytic, suitable for the treatment of generalised anxiety disorder [93]. Receptors 
containing 5 subunits confer to learning and temporal and spatial memory. The 5 subunit 
of the GABAA receptor is localized mainly to the hippocampus of the mammalian brain. It is 
shown that the largely extrasynaptic 5 GABAA receptors in hippocampal pyramidal cells are 
implicated as control elements of the temporal association of threat cues in trace fear 
conditioning [94]. Furthermore, the 5 -/- mice showed a significantly improved performance 
in a water maze model of spatial learning, indicating that 5-containing receptors play a key 
role in cognitive processes [95]. However, as pointed by Sigel and Steinmann [5], behaviour 
is a complex phenomenon, and caution is needed in an attempt to define the role of individual 
GABAA receptor subunits, as most probably several types of GABAA receptors determines 
even the simple behavioural traits. Receptors containing α4 and α6 subunits are generally 
thought as insensitive to classical benzodiazepine agonists [96,97], although they retain a high 
affinity for the partial inverse benzodiazepine agonist Ro 15-4513 [98]. Unusually, specific 
high-affinity binding of the benzodiazepine agonist flunitrazepam to α6β2γ2-containing 
GABAA receptors was shown [99], but flunitrazepam action on α6β2γ2-receptors was 
opposite to its action on α1β2γ2-receptors where it exhibits an inverse agonistic effect in a 
GABA-dependent manner.  
Benzodiazepines bind with high-affinity to a binding site located at the α/γ subunit 
interface in the extracellular domain of GABAA receptor [65,100]. The binding site for 
benzodiazepines is formed by one of α subunits (α1, α2, α3 or α5) and a γ subunit (typically 
the γ2 subunit, which is present in approximately 90% of all GABAA receptors) [4]. Studies 
on recombinant GABAA receptors indicated that co-expression of α, β and γ subunits is 
required for arrangement of high-affinity binding sites at GABAA receptor complex [101]. 
Hanson and Czajkowsky [102] have identified that Gln182-Arg197 region of γ2 subunit is 
part of the allosteric pathway that allows propagation of structural changes induced by 
positive benzodiazepine modulators through the protein to the channel domain. Furthermore, 
several amino acid residues on α and γ subunits have been identified that are crucial for 
benzodiazepine activity and form benzodiazepine binding pocket [86,103-105]. It is 
considered that antagonists bind in a pocket partly overlapping with the agonist site, although 
they can extend further into the solvent accessible cavity [106].  
Richter et al. [107] described a binding mode for diazepam and analogs. By using this 
binding hypothesis and virtual screening approaches, they identified numerous known ligands 
of benzodiazepine-binding site from different structural classes and predicted potential new 
chemotypes for this site, thus demonstrating its suitability for drug discovery and structure-
based drug design which is of major therapeutic importance. According to the model, 
although hundreds of ligands from different structural classes can bind to the benzodiazepine-
binding sites, only a minority is bound to the same bioactive conformation as diazepam. 
Evidence exists that some benzodiazepines can also bind to additional binding sites on 
GABAA receptor complex. Walters et al. [108] demonstrated that in the presence of low 
concentrations of GABA, diazepam produces a biphasic potentiation of α1β2γ2-receptor 
channels, with distinct components in the nanomolar and micromolar concentration ranges. 
Mutations at equivalent residues within the second transmembrane domains (TM2) of α, β 
and γ subunits abolished only the micromolar component, while nanomolar component, which 
depends on the presence of γ2 subunit, was not affected. Similarly, converse mutation of the 
corresponding TM2 residue and a TM3 residue within ρ1 subunits confers diazepam 
sensitivity on homo-oligomeric ρ1-receptor channels that are otherwise insensitive to 
benzodiazepines. Furthermore, effect of micromolar component on the GABA-induced 
current was not inhibited by flumazenil, an antagonist of benzodiazepine binding sites. As 
these transmembrane domains are important for effects of anesthetics, and taking into account 
anesthetic properties of diazepam, it might be that low potency modulation is elicited via 
anesthetic binding site [66]. 
In contrast to diazepam that act as positive allosteric modulator in both nanomolar and 
micromolar range, β-carbolines, such as methyl-6,7-dimethoxy-4-ethyl--carboline (DMCM),  
act as negative allosteric modulators at high affinity sites, but potentiate effects of GABA via 
the low-affinity binding sites [109]. The apparent reversal of inhibition and potentiation by 
high concentrations of DMCM is insensitive to flumazenil, β2/3 subunit dependent, and 
probably elicited via the binding site for anticonvulsant loreclezole in the transmembrane 
domain. Moreover, Baur et al. [110] found evidence for the presence of a third site for 
benzodiazepines that prevents modulation of GABAA receptors via the classical 
benzodiazepine site. The novel site potentially contributes to the high degree of safety to some 
of these drugs. Their results indicate that this site may be located at the α/β subunit interface 
pseudo-symmetrically to the site for classical benzodiazepines located at the α/γ interface.  
In addition, it is found that the specific effects of imidazobenzodiazepine Ro15-4513 
in antagonizing ethanol-stimulated 36Cl- uptake and behaviour can be completely blocked by 
benzodiazepine receptor antagonists. As other benzodiazepine receptor inverse agonists fail to 
antagonize the actions of ethanol in vitro or in vivo, a novel binding site for Ro15-4513 is also 
hypothesized [111]. Hanchar et al. [112] demonstrated that extrasynaptic δ subunit-containing 
receptors bind the imidazo-benzodiazepines flumazenil and Ro15-4513 with high affinity, 
contrary to the widely held belief that these receptors are benzodiazepine insensitive. 
Recently, it was identified that in addition to benzodiazepine binding site, Ro15-4513 
interacts with high affinity to sites at the α4/6+β3- interface (each subunit has a plus and 
minus side determined by the absolute arrangement of subunits around central pore) and thus 
inhibits ethanol effects [98]. 
As for some potential binding sites no interacting drugs have been identified, 
Ramerstorfer et al. [113] established a steric hindrance procedure for the identification of 
drugs acting at the extracellular α1+β3– interface, which is homologous to the benzodiazepine 
binding site at the α1+γ2– interface, while GABA-binding sites are located at the β+– 
interface [66]. Among screened compounds, anxiolytic pyrazoloquinoline 2-p-
methoxyphenylpyrazolo[4,3-c]quinolin-3(5H)-one (CGS 9895) was able to enhance GABA-
induced currents at α1β3 receptors from rat. Thus, at nanomolar concentrations CGS 9895 
behaves as an antagonist of high-affinity, benzodiazepine binding site, but exerts a low-
potency positive modulatory action at the extracellular α+β– interface of α1β3γ2 and α1β3 
receptors. Other experiments indicated that the CGS 9895 effect was dependent on α and β 
subunit isoforms forming the interface. Since CGS 9895, even at high concentrations, was 
only able to enhance GABA-induced currents but not directly activate these receptors, it is 
likely that drugs acting via the α+β− interface only have GABA-modulatory properties, like 
the benzodiazepines do. In contrast to benzodiazepines, these drugs will interact with 
receptors composed of αβ, αβγ, and αβδ subunits. Hence, they would exhibit a much broader 
anticonvulsive action than benzodiazepines, which might be of clinical importance for the 
treatment of epilepsy and development of subtype-selective drugs.  
Based on results obtained with crystal structure of ELIC, prokaryotic homolog of 
GABAA receptor, it is possible that at least some benzodiazepines, such as flurazepam, may 
directly interact with the GABA-binding site at β+α- interface at high concentration and 
displace GABA from its binding site, although these effects are observed only at high 
concentrations and further experiments are needed to confirm if this site has a functional role 
in GABAA receptors [66,114].  
Unfortunately, despite their proven clinical efficacy, positive modulators of 
benzodiazepine binding sites at GABAA receptor possess a relatively narrow window between 
doses that produce anxiolytic effects and those that cause sedation, and are associated with the 
development of tolerance and physical and psychological dependence and a potential for 
abuse [115-117]. Hence, strategy to resolve the disadvantages of classical full agonists was 
directed toward development of partial agonists with lower intrinsic efficacy. A number of 
non-selective partial agonists with reduced intrinsic efficacy, including bretazenil, 
pazinaclone and abecarnil, were described. In general, although they have a large window 
between anxiolytic and sedative doses and their dependence and abuse liabilities were much 
lower, they failed to translate into clinical benefit [93]. More recently, the imidazolone 
derivatives imepitoin was shown to act as low-affinity partial agonist at the benzodiazepine 
site of the GABAA receptor, and was approved for the treatment of epilepsy in epileptic dogs 
due to its more favorable pharmacokinetic profile in dogs versus humans, reactivating again 
the interest for partial benzodiazepine agonists for the treatments of human epilepsy [118]. 
Regarding development of tolerance and dependence to benzodiazepine-site ligands 
after prolonged administration, diverse effects at the molecular and cellular level have been 
described, including receptor desensitization and changes in the number and subunit 
composition of surface GABAA receptors, often leading to decreased ability of 
benzodiazepines to potentiate effects of GABA [17,119-124].  
 
Effects of convulsants at GABAA receptor 
 
Very early picrotoxin was identified as a noncompetitive inhibitor of GABAA 
receptor. Binding studies further revealed that numerous compounds from heterogeneous 
chemical classes posses affinity for picrotoxin-binding sites, including t-
butylbicyclophosphorothionate (TBPS), t-butylbicycloorthobenzoate (TBOB), 
pentylenetetrazole, and some insecticides (such as dieldrin and lindane). They inhibit GABA-
induced influx of chloride ions acting as allosteric antagonists at GABAA receptor complex 
[125-128].  
TBPS partially and allosterically inhibits binding of GABA and positive modulators of 
GABAA receptors, but facilitates binding of negative modulators. Similarly, modulators of 
GABAA receptor function affect [
35S]TBPS binding. GABA exhibits biphasic effect on the 
allosteric modulation of [35S]TBPS binding. Thus, [35S]TBPS binding was allosterically 
inhibited by high concentrations of GABA, GABA agonists and other positive modulators 
(various benzodiazepine receptor agonists, anesthetics and pentobarbital) and promoted in the 
presence of negative modulators such as ethyl-β-carboline-3carboxylate (β-CCE). On the 
contrary, GABA applied at low concentrations enhanced [35S]TBPS binding [6,36,129-132]. 
In addition, the effects of the anesthetic steroid and pentobarbital on [35S]TBPS binding were 
markedly altered by GABA, which at 2 μM increased their maximal effects and half-maximal 
concentrations. On the contrary, GABA did not affect changes in [35S]TBPS binding 
produced by various benzodiazepine receptor agonists, indicating more pronounced functional 
coupling of the GABA sites with those for the steroid and the barbiturate, as compared with 
the benzodiazepine site. Hence, it appears that the degree of [35S]TBPS binding in the 
presence of GABA reflects the functional state of GABAA receptors and may be useful for 
characterization of allosteric interactions between various sites on the receptor [6,133].  
Inhibitory effects of GABA on [35S]TBPS binding are determined by α subunit 
isoform. It has been shown that expression of recombinant α6β2γ2 GABAA receptors 
produces [35S]TBPS binding sites that are about 10-fold more sensitive to inhibition by 
GABA than were those inherent to α1β2γ2 GABAA receptors. Similarly, the neurosteroid 5α-
pregnan-3α-ol-20-one (allopregnanolone) affected the binding in both α1β2γ2 and α6β2γ2 
receptors, but inhibition was greater in α6-containing than in α1-containing receptors, also 
suggesting differential coupling of both GABA and neurosteroid sites with the convulsant site 
[134]. 
At first, it was suggested that picrotoxin's site of action is probably within the channel 
pore as mutations in TM2 domains (that form chloride channels) produced currents that were 
insensitive to picrotoxin [135]. By convention, Cys-loop receptor TM2 residues are numbered 
from intracellular 0 to extracellular 20 positions. Although the exact location of picrotoxin 
binding to ionophore is still unknown, its sensitivity to mutations in residues 2/3 and 6 of 
TM2 indicates that the site contains residues 2–6. In particular, it is suggested that picrotoxin 
enters deep inside the ionophore pore, binds with its hydrophobic moiety to residue 2 of TM2 
(close to the pore) and forms hydrogen bounds with residue 6 in the middle of TM2. Residue 
15 is probably important for interplay between GABA and picrotoxin binding sites. Other 
studies implicated residues 9 and 15 in the regulation of channel properties, including 
desensitization, stabilization of open states and gating. This indirectly supports the possibility 
of a second “modulatory” (allosteric) binding site of picrotoxin including residues 15–19 
[128]. 
Dillon et al. [136] provided evidence that picrotoxin and TBPS interact with GABA-
bound and -resting receptors, but their affinity for GABA-bound receptors is about 10 times 
greater, largely due to a markedly increased association rate to the multi-liganded receptors. 
Accordingly, TBPS and picrotoxin are considered as open channel blockers. However, 
[35S]TBPS binds to recombinant receptors in the absence of GABA [130]. Hence, it does not 
gain access to its binding site via the open pore but through alternative routes regulated from 
the agonist binding site [137]. It is shown that picrotoxin displaceable [35S]TBPS binding to 
α1β2γ2 GABAA receptors might occur in the absence of GABA, suggesting that access to the 
binding site is independent of activation. In fact, bicuculline-sensitive spontaneous gating 
contributes to [35S]TBPS binding in the absence of GABA by providing access to the channel. 
Accordingly, a decrease in a spontaneous gating reduces accessibility of TBPS to its binding 
site [132]. GABA application during picrotoxin or TBPS administration enhanced α1β2γ2 
receptor blockade, and this GABA-dependent component of TBPS blockade accounts for the 
stimulation of [35S]TBPS binding to α1β2γ2 receptors seen with low concentrations of 
GABA, while application of GABA at concentrations that cause significant steady-state 
desensitization reduces [35S]TBPS binding [132].  
 
Effects of anesthetics at GABAA receptor 
 
General anesthetics are used to induce a reversible loss of consciousness in surgical 
patients and to relieve pain. GABAA receptors are the major site of action of clinically used 
intravenous anesthetics such as etomidate, propofol, barbiturates and neuroactive steroids. On 
the other hand, clinically used volatile anesthetics such as isoflurane and enflurane, and long-
chain alcohols, presumably act via a multitude of targets, GABAA receptors being just one of 
them [4,63,138,139].  
In general, GABAA receptors are positively modulated by clinical doses of anesthetics, 
while at higher concentrations anesthetics can directly activate GABAA receptors [63,140]. 
Accordingly, many studies were aimed to identify binding site(s) for anesthetics on GABAA 
receptors, which are generally considered as the main target for propofol and etomidate action 
as already mentioned. Belelli and co-authors [141] have shown that the ability of etomidate to 
modulate and activate GABAA receptors in vitro is uniquely dependent upon the  subunit 
subtype present within the receptor, i.e. receptors containing 2- or 3-, but not 1 subunit, 
are highly sensitive to etomidate. They identified a region distal to the extracellular N-
terminal domain as a determinant of the selectivity of etomidate: mutation of Asn present 
within the channel domain of the 3 subunit to Ser (the homologous residue in 1) strongly 
suppressed the GABA-modulatory and GABA-mimetic effects of etomidate. Later, it was 
confirmed that the same point mutation (Asn265Met) completely abolished the suppression of 
noxious-evoked movements in response to propofol and etomidate in a knock-in mouse, while 
only slightly decreased in response to volatile anesthetics enflurane and halothane. Mice also 
displayed a profound reduction in the loss of righting reflex duration (a surrogate for loss of 
consciousness) in response to intravenous but not volatile anesthetics. Accordingly, 
electrophysiological recordings revealed that anesthetic agents were significantly less 
effective in enhancing GABA-induced currents in cortical brain slices derived from mutant 
mice, thus identifying the key molecular determinant of behavioural responses evoked by 
intravenous anesthetics [142].  
Studies on recombinant receptors have revealed that isoforms of α, γ and δ subunits 
affect propofol modulation of the GABAA receptor, although it seems likely that the propofol 
binding site involves the β subunit (see below). In order to investigate the role of α subunit in 
the modulatory effects of propofol, Krasowski et al. [143] used whole-cell patch clamp 
recordings from cells expressing only α1β3γ2 or α6β3γ2 subtypes, and found that at clinically 
relevant concentrations, propofol potentiated submaximal GABA currents in α1β3γ2 receptors 
to a far greater degree than in α6β3γ2 receptors. Isoform of α subunit influenced the efficacy 
of propofol for modulation, but not its potency. On the contrary, direct gating of the chloride 
channel was significantly larger in the α6β3γ2 receptors. A same trend for potentiation and 
direct gating was observed for other anesthetics. Similarly, pharmacological properties of 
human recombinant GABAA receptors were studied in Xenopus oocytes expressing α1β2, 
α1β2γ2L, or α2β2γ2L receptor isoforms. In all receptor isoforms tested, propofol potentiated 
the GABA-activated currents in a concentration-dependent manner, and was able to directly 
activate all three receptor isoforms. Addition of the γ2L subunit to the α1β2 isoform reduced 
receptor sensitivity to direct activation, while replacement of the α1-subunit with the α2-
subunit increased receptor sensitivity to propofol's direct effects, indicating that isoforms of α 
and γ subunits have the ability to influence both the direct and modulatory actions of propofol 
on GABAA receptor function [144]. Jones et al. [140] reported that γ2 subunit is not a 
prerequisite for activation of GABAA receptors by propofol or for its potentiation of GABA-
activated currents, but showed that it may contribute to the efficacy of propofol as a GABAA 
receptor activator. Furthermore, the findings that propofol reduced desensitization and 
prolonged deactivation of receptors containing γ2L subunit and enhanced peak currents or 
prolonged deactivation of receptors containing δ subunit suggest that propofol-induced 
enhancement of both phasic and tonic inhibition may contribute to its anesthetic effect in the 
brain [145]. In accordance with mentioned studies, mutations in α and γ subunits change 
modulatory effects of propofol at the GABAA receptors [146,147], while particular residues in 
β subunits, distributed throughout the membrane-spanning region of the receptor, as well as in 
the extracellular domain, determine the propofol’s actions. Thus, a point mutation in the β1 
subunit (Met286Trp) abolished potentiation of GABA by propofol, but did not alter direct 
activation of the receptor by high concentrations of propofol [148]. The same mutation had 
the same effect in the β2 subunit, probably by altering the dimensions of a binding pocket for 
propofol and related alkylphenol general anesthetics [149]. One mutation in β2 subunit 
(Tyr444Trp) was particularly interesting, as it selectively suppressed the ability of propofol to 
enhance receptor function, while retaining normal sensitivity to etomidate [150]. 
Although various anesthetics do not bind to the same binding site and exhibit distinct 
structural requirements for modulatory and direct actions, it seems that main sites of action 
are located close to each other, within the transmembrane domain [151]. The influence of the 
large intracellular loop in propofol sensitivity has also been recognized. Moraga-Cid et al. 
[147] have shown that mutation of a conserved Phe385 residue within the α1 large 
intracellular loop significantly reduced propofol enhancement, although propofol-
hyposensitive mutant receptors retained their sensitivity to other allosteric modulators such as 
alcohols, etomidate, trichloroethanol, and isoflurane. At the single-channel level, the ability of 
propofol to increase open probability was significantly reduced, altogether suggesting a new 
role of the large intracellular loop in allosteric modulation, and providing new insight into the 
propofol-mediated modulation of GABAA receptor complex. By using a novel propofol 
analogue photolabeling reagent, Yip et al. [152] have identified a novel binding site for 
propofol in β3 homopentamers and α1β3 heteropentamers. The binding site is located within 
the β subunit, at the interface between the transmembrane domains and the extracellular 
domain, and lies close to known determinants of anesthetic sensitivity in transmembrane 
segments TM1 and TM2.  
The similar approach was used to determine binding site for etomidate. By using 
radiolabeled, photoreactive etomidate analogs, residues αMet-236 and βMet-286 in the αTM1 
and βTM3 transmembrane helices, were identified as a part of single binding pocket in the 
transmembrane domain at the β+α- interface, close to the extracellular domain, bellow the 
GABA-binding site. Such localization of the etomidate binding site to an inter-subunit, not an 
intra-subunit binding pocket was an interesting finding, suggesting that binding sites at 
subunit interfaces may be a feature not only for GABA and benzodiazepines, but also for 
etomidate and other anesthetics [153,154]. As photolabeled etomidate analog was also 
displaced by isoflurane, Li et al. [139] suggested that inhalation anesthetics also interact with 
this binding site. More precisely, in their study photolabeling was inhibited by low millimolar 
anesthetic concentrations of propofol, barbiturates, and isoflurane, but not by octanol or 
ethanol. Inhibition by barbiturates and propofol was only partial, consistent with allosteric 
interactions, whereas isoflurane inhibition was nearly complete, suggesting competitive 
interactions.  
 
Effects of barbiturates at GABAA receptor 
 
Response of GABAA receptors may also be modulated by barbiturates. They have 
been used in the past due to their anticonvulsant, anxiolytic, sedative, and hypnotic actions, 
but they exert serious side effects, including profound depression of CNS activity with the 
induction of pronounced sedation, cognitive slowing or confusion, hyperactivity in children 
and a lethal risk in a case of overdose [155-157].  
As they bind to GABAA receptor with low affinity, most of their actions have been 
analysed indirectly by studying interactions with other binding sites. Barbiturates enhance 
binding of GABA and benzodiazepines, whereas inhibit binding at convulsant binding site 
[158]. Depending on the concentration, barbiturates act in three different ways, and their 
effects are proportional to anesthetic potency. At low µM (sub-anesthetic) concentrations they 
potentiate GABA-induced effects (modulatory effect) and prolong duration of open 
conformation of chloride channel, possibly by stabilizing open state(s). In higher µM 
(anesthetic) concentrations (app. >50 µM) they directly open chloride channel (agonistic 
effect), whereas at very high mM concentrations block GABA-induced current (inhibitory 
effect) [159,160]. More precisely, when co-applied with low concentrations of GABA, 
barbiturates increased the mean open time. The increase in channel open time results in 
greater chloride current flux and increased likelihood that channel openings will summate, 
producing larger inhibitory currents [157]. In the absence of GABA, high concentrations of 
barbiturates may directly activate GABAA receptor chloride currents, although with lower 
efficacy than GABA [60]. All these effects are probably mediated by separate mechanisms. In 
support of this conclusion, it was demonstrated that mutation of Thr262 in the transmembrane 
domain of β1 subunits at α1β1 recombinant GABAA receptors abolished modulatory effect, 
without affecting direct agonistic or inhibitory effects of pentobarbital [161].  
Although barbiturate sensitivity does not require a specific subunit composition, their 
effects are also determined by subunit composition [57,157]. Isoforms of α subunit affect 
efficacy, but not affinity of barbiturates in potentiation of GABA response. In contrast to 
benzodiazepines that are ineffective at GABAA receptors containing α4 or α6 subunit, 
barbiturates elicit modulatory effects at receptors containing these isoforms [97,159], and the 
isoform of α subunit influences the level of potentiation [162]. Related to agonistic activity, 
the type of α subunit present determines both the degree of affinity and efficacy observed. 
Receptors containing α6 isoform produce maximum direct response to barbiturate 
pentobarbitone, larger than that obtainable with maximum GABA, and larger than that 
obtainable with other α subunits. GABAA receptors containing α6 subunits also have higher 
affinity for direct activation by pentobarbitone. Furthermore, the direct effect of 
pentobarbitone can be blocked by picrotoxin, but not by competitive antagonists, such as 
bicuculline [97,159]. Surprisingly, unlike receptors containing α6 isoform, α4β1γ2 receptors 
did not elicit any direct activation of GABAA receptors by pentobarbital [97].  
Some amino acid residues have been identified with major impact on barbiturate 
activity. An invariant proline residue in transmembrane domain TM1 is included in a 
consensus motif of all GABAA receptor subunits. Proline in TM1 segment of β1 subunit 
affects the linkage between GABA binding and channel gating and is critical for barbiturate 
enhancement at recombinant GABAA receptors, without affecting enhancement by diazepam 
or neurosteroid alfaxalone [163]. Gly219 near the TM1 at β2 subunit is also identified as 
important for allosteric (modulatory) effects of pentobarbital since pentobarbital-induced 
enhancement of [3H]muscimol and [3H]flunitrazepam binding in receptors containing the 
β2(Gly219Phe) point mutation displayed a significantly reduced efficacy in modulation. 
Furthermore, functional analysis of pentobarbital-enhanced GABA currents recorded with 
whole-cell patch clamp demonstrated that this mutation eliminates the potentiating effect of 
the anesthetic. Interestingly, the α1β2(Gly219Phe)γ2 receptors also were more sensitive to 
direct channel activation by pentobarbital, suggesting that Gly219 may be important for 
conformational or allosteric interactions of channel gating by GABA and barbiturates [164].  
Chiara et al. [165] used a photoreactive barbiturate analog to determine residues 
important for barbiturate binding site. It photolabeled sites at the α+β- and γ+β- subunit 
interfaces in the transmembrane domain, near the synaptic side. These binding sites are 
distinct but homologous to the etomidate sites at the two β+α- subunit interfaces, as all are 
located at the same depth in the transmembrane domain. They demonstrated that 
photoreactive barbiturate and etomidate derivatives are highly selective for their own sites, 
indicating that there are two structurally related, but pharmacologically distinct, classes of 
inter-subunit general anesthetic-binding sites in the transmembrane domain of human α1β3γ2 
GABAA receptors. They hypothesized that binding at any of these homologous inter-subunit 
sites is sufficient for anesthetic action. Namely, a wide range of general anesthetic structures 
target these four sites but with variable selectivity, which offers an explanation of the puzzling 
lack of well defined structure-activity relationships among general anesthetics. More 
importantly, these findings indicate that it may be possible to synthesize general anesthetics 
with specificity for sites between specific subunits in the transmembrane domain of 
pentameric GABAA receptors, with a hope to target specific nerve pathways and behaviours 
in a subunit-dependent manner in the future [165].  
 
 
Effects of neurosteroids at GABAA receptors 
 
Inhibitory neurotransmission mediated by GABAA receptors can be modulated by 
endogenous neurosteroids, mostly metabolites of progesterone and deoxycorticosterine, 
including allopregnanolone and tetrahydrodeoxycorticosterone (THDOC). In general, they 
potently enhance function of synaptic and extrasynaptic GABAA receptors by an allosteric 
mechanism [31,40,166,167]. Neurosteroids possess distinct, characteristic effects on the 
membrane potential and current conductance mainly via potentiation of GABAA receptors at 
low doses, and direct activation of receptor chloride channel at higher concentrations. As a 
results, upon administration neurosteroids exert anxiolytic, analgesic, anticonvulsive, sedative 
and hypnotic effects, while applied at higher doses may induce a state of general anesthesia 
[40,168-171]. Although the most important effects of neurosteroids are mediated via GABAA 
receptors, they also exert various effects on an array of ligand-gated ion channels and distinct 
G-protein-coupled receptors via nongenomic mechanisms, including the N-methyl-D-
aspartate (NMDA), alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA), 
kainate, glycine, serotonin, sigma type-1, and nicotinic acetylcholine receptors [156,172]. 
Besides modulation of diverse receptors, the other functions attributed to specific 
neurosteroids include neuroprotection, for example against glutamate-induced excitotoxicity, 
and induction of neurite outgrowth, dendritic spines and synaptogenesis, and contribution to 
the behavioural effects of psychoactive drugs [49,51,173-175]. 
As emphasized before, neurosteroids exhibit two modes of action at GABAA 
receptors. They allosterically modulate channel opening, and at high concentrations act as 
GABA-mimetics and directly open the chloride channel [31,53,176]. Two discrete binding 
sites in the receptor’s transmembrane domains have been identified that mediate the 
potentiating and direct activation effects of neurosteroids. Neurosteroids potentiate GABA 
responses from a cavity formed by the α-subunit transmembrane domains, while direct 
receptor activation is achieved by interfacial residues between α and β subunits and is 
additionally enhanced by steroid binding to the potentiation site, indicating that activation of 
GABAA receptors by neurosteroids relies on the occupancy of both sites [177]. Further work 
provided a more detailed kinetic and pharmacological characterization of the effects of 
mutations on channel activation and modulation by neurosteroids, leading to a model where 
residues in the TM1 membrane-spanning domain shape the binding surface to accommodate a 
variety of structurally distinct neurosteroids [178]. The potentiating effect of neurosteroids 
can be mediated by steroid interactions with its site within the same β-α pair that mediates 
receptor activation as well as the opposite β-α pair [179]. Chisary et al. [180] have shown that 
neurosteroids require a membranous route of access to transmembrane-domain binding sites 
that might have implications for the design of novel neuroactive steroids because their lipid 
solubility and related accessibility are probably the key determinants of receptor modulation 
[180]. This also suggests that by virtue of their high lipid solubility, µM concentrations of 
neurosteroids may be achieved locally [31]. 
Neuroactive steroids may act both as positive and negative modulators of GABAA 
receptor function. Applied at concentrations below 300 nM, they are positive allosteric 
neuromodulators as they facilitate conformational transition of the GABA-gated chloride 
channel to an open state, increase mean channel open time and consequently increase GABA-
elicited chloride currents [49,131,181-183]. Furthermore, they modulate binding of GABA 
agonists, increase binding of positive modulators at benzodiazepine binding sites, and 
enhance TBPS binding in the absence of GABA [184-187]. On the contrary, sulphated 
endogenous steroids like pregnenolone sulphate and dehydroepiandrosterone sulphate 
(DHEAS) act as negative modulators at steroid binding site when applied at µM 
concentrations [59]. For various neuroactive steroids sulfation at C-3 reverses the direction of 
modulation from positive to negative, suggesting that sulfation could be an important control 
point for the activity of endogenous neurosteroids. As interactions of positive and negative 
steroid modulators are not competitive, they probably act via distinct binding sites at GABAA 
receptor. This implies that negative and positive steroid modulators can act independently or 
coordinately to regulate GABA-mediated inhibition in the CNS [188]. Antagonistic 
neurosteroids may shorten the channel open time and enhance GABA-induced desensitization 
[6].  
Similarly to other binding sites, subunit assembly determines sensitivity and 
pharmacological effects of neuroactive steroids. Studies on recombinant GABAA receptors 
have revealed that presence of δ subunit confers increases sensitivity to neurosteroid 
modulation by affecting intrinsic gating and desensitization kinetics [181,189]. Thus, at 
concentrations known to occur in vivo, neuroactive steroids specifically enhance a tonic 
inhibitory conductance in central neurons that is mediated by extrasynaptic δ subunit-
containing GABAA receptors [190]. In addition, expression of extrasynaptic GABAA 
receptors is dynamically regulated by neuroactive steroids. For example, it is suggested that 
neuroactive steroids mediate a stress-induced enhancement in the expression of α4βδ 
receptors, probably contributing to observed stress-related memory impairment [41,44,191]. 
Potency and efficacy of neuroactive steroids is also determined by other subunits. Although 
these differences are not very pronounced, even small differences in receptor sensitivity might 
be physiologically relevant. Namely, allopregnanolone concentrations in plasma are 3-10 nM 
in physiological conditions, and increase only to 30-60 nM during stress [168].  
Interestingly, it is confirmed that endogenous neurosteroids profoundly affect neuronal 
activity at particular receptor isoform. For example, it is shown that α1β2δ subtype of 
GABAA receptors presumably expressed in the forebrain, exhibits an extremely small GABA-
mediated current in the absence of the modulator, but in the presence of THDOC exerts a 
profound inhibitory influence on neuronal activity by increasing maximum current amplitude 
and decreasing half-maximal concentration (EC50) of GABA [192]. Hence, depending on the 
subunit composition, GABA-modulatory effects of physiological levels of the neurosteroid 
are not uniformly experienced throughout the CNS, or even within the same brain region. In 
addition, these modulatory effects are determined by the phosphorylation status of the 
GABAA receptor, or associated proteins, and by local steroid metabolism [31,49,54,193].  
As endogenous ligands, neuroactive steroids may modulate diverse physiological and 
pathophysiological conditions, regulating GABAA receptor-associated functions and 
behaviour. Altered neurosteroid levels are associated with psychiatric and neurological 
disorders, including premenstrual dysphoric disorder, premenstrual syndrome, menstrual 
migraine, postpartum depression, pain disorder, catamenial epilepsy, major depression, 
schizophrenia, alcohol dependence and anxiety [51,177,194]. The pathogenesis of these 
diseases remains unclear, partly due to the lack of useful animal models to study such 
complex disorders [46]. As mentioned before, pregnancy is associated with a pronounced 
enhancement in progesterone-derived neurosteroid levels, with sharp decline after delivery. 
Because neuroactive steroids exert anxiolytic effects, neurosteroid withdrawal could play role 
in the pathophysiology of postpartum depression [195]. Synthetic neurosteroids that exerts 
better bioavailability and efficacy, as well as drugs that enhance neurosteroid synthesis and 
lack unwarranted side effects of benzodiazepines, are therefore considered as potential 
therapeutics in the treatment of anxiety, epilepsy and other brain disorders [156,195-197].  
 
 
Effects of ethanol at GABAA receptors 
 
Ethanol is often classified as modulator of GABAA receptor activity. It is without 
doubt that very high concentrations of ethanol modulate activity of diverse membrane 
proteins, including GABAA receptors [198]. However, it is not quite clear whether social 
ethanol intake (<20 mM) really exerts effects on human behaviour via GABAA receptors [5]. 
Wallner and co-authors [199] have demonstrated that GABAA receptors might be enhanced 
by ethanol concentrations that are reachable by moderate, social consumption. They found 
that GABAA receptors responsive to these low concentrations require presence of δ-subunit, 
which is thought to be associated exclusively with α4- and α6-subunits, and the β3-subunit. 
Their finding also suggests that extrasynaptic GABAA receptors are primary targets for 
ethanol. Later, Borghese and co-workers [198] failed to replicate the sensitivity of α4β3δ 
GABAA receptors to low concentrations of ethanol at rat and human recombinant GABAA 
receptors expressed in Xenopus oocytes. In addition, in their study ethanol at 30 mM 
concentration did not affect tonic GABA-mediated currents in dentate gyrus reported to be 
mediated by α4β3δ subtype of GABAA receptors. Similarly, in another study, α6β3δ GABAA 
receptors were expressed in Xenopus oocytes and were not modulated by physiological 
concentrations (up to 30 mM) of ethanol [200].  
On the other hand, prolonged ethanol consumption that leads to the development of 
alcohol dependence induces changes of GABAA receptor subunits at transcriptional and 
translational levels in brain area-specific manner, including reduction in  subunit expression 
in the orbitofrontal cortex, cerebellum, hippocampus and amygdala. Changes in receptor 
composition might have important consequences for GABAergic neurotransmission, plasticity 
and behaviour including impairment in memory, anxiety, and executive and motor functions 
[201-203]. Furthermore, it was found that ethanol at concentrations of 20 to 100 mM 
stimulates GABA-mediated uptake of chloride ions in isolated brain vesicles, and this effect 
can be blocked by the imidazobenzodiazepine Ro15-4513. Pre-treatment of rats with Ro15-
4513 blocks the anticonflict activity of lower doses of ethanol, and behavioural intoxication 
observed with higher doses of ethanol. These effects of Ro15-4513 in antagonizing ethanol-
stimulated 36Cl- uptake and behaviour can be completely blocked by benzodiazepine binding 
site antagonists, indicating that neuropharmacological actions of ethanol (20-100 mM) may be 
mediated via central GABA receptors [111]. Similarly, it was shown that [3H]Ro15-4513 
binding is inhibited only by those benzodiazepine-site ligands that reverse the behavioural 
alcohol antagonism of Ro15-4513 such as flumazenil and β-carboline-3-carboxylate ethyl 
ester (β-CCE), but not by any classical benzodiazepine agonists. Additional experiments 
indicated that ethanol and Ro15-4513 occupy mutually exclusive binding sites. Since only 
Ro15-4513, but not flumazenil, can inhibit ethanol effects, and taking into account that Ro15-
4513 differs from flumazenil by only a single group at the C7 position of the benzodiazepine 
ring, it is assumed that this group in Ro15-4513 might be the area that overlaps with the 
alcohol-binding site. Hence, it turns out that many of the behavioural effects of ethanol at 
relevant physiological concentrations are mediated via ethanol/Ro15-4513-sensitive GABAA 
receptors [112]. 
Wallner and co-workers [98] showed that differences in alcohol sensitivity toward β 
subunits are determined by the extracellular N-terminal part of the protein. By using point 
mutations, they discovered that the β3 alcohol selectivity is determined by a single amino acid 
residue in the N-terminus that differs between β subunits (β3Tyr66, β2Ala66, β1Ser66). The 
β3Tyr66 residue is located in a region which in γ subunits contributes to the 
imidazobenzodiazepine binding site at the classical α+γ2- subunit interface. Furthermore, they 
proposed a model in which β3 and δ containing GABAA receptors form a unique ethanol site 
at the α4/6+β3- subunit interface. As this site is homologous to the classical benzodiazepine 
binding site, it also has high affinity for a few selected benzodiazepine site ligands including 
alcohol antagonistic Ro15-4513 that bears large moiety at the C7 position of the 
benzodiazepine ring. They also suggested that large moieties at the C7-benzodiazepine ring 
compete with alcohol for its binding pocket at a α4/6+β3- ethanol/Ro15-4513 site, thus finally 
providing explanation for the competitive relationship between ethanol and 
imidazobenzodiazepine antagonists.  
 
 
Interactions of flavonoids with GABAA receptor 
 
Flavonoids represent a heterogeneous class of plant secondary metabolites. They exert 
a wide-range of health-promoting effects including antioxidative, anti-inflammatory, 
cardioprotective, anticarcinogenic, antidiabetic and neuroprotective activities [204-206]. Like 
many neuroactive drugs, they achieve their effects, at least in part, by modulating GABAA 
receptors [207,208]. Radioligand binding studies indicated that flavonoids exert a selective 
affinity for the benzodiazepine binding site at GABAA receptor complex, mostly acting as 
partial agonists [209]. Although it is initially thought that they act on classical, “high-affinity” 
benzodiazepine binding sites, many flavonoid actions are not inhibited by classical 
benzodiazepine antagonist flumazenil. For example, Hall et al. [210] have shown that 6-
methoxyflavanone and 6-methoxyflavone act as flumazenil-insensitive positive allosteric 
modulators of GABA responses at human recombinant 122L and 222L GABAA 
receptors. Functional electrophysiological studies suggest that flavonoids act on GABAA 
receptors via two separate mechanisms: by acting on flumazenil-sensitive high-affinity site 
and an alternative site that may be the flumazenil-insensitive low-affinity benzodiazepine site 
[208]. However, as in aforementioned study 6-methoxyflavanone inhibited [3H]-
flunitrazepam binding whilst remaining unaffected by flumazenil, this might suggest a novel 
allosteric binding site that is independent of both the high-affinity and low affinity 
benzodiazepine binding sites [210].  
More importantly, some flavonoids may directly open certain subtypes of GABAA 
receptors in the absence of GABA [208]. Behavioural studies demonstrated anxiolytic effects 
of flavonoids in animal models. Some of the tested flavonoids (e.g. chrysin) have anxiolytic 
effects similar to diazepam, but not associated with myorelaxant, sedative or amnesic actions, 
suggesting that they could lead to improved therapeutic drugs in the treatment of anxiety 
[211,212]. However, in addition to positive modulation, flavonoids may also achieve negative 
effects on GABAA receptors [213,214]. Some flavonoids are positive neuromodulators when 
applied in the presence of low concentrations of GABA, but in the presence of high 
concentrations of GABA act as negative modulators [215]. A range of natural flavonoids act 
as negative modulators of receptors containing ρ-subunits. 
Recently, it was found that quercetin and its glycosides inhibit GABA-induced inward 
current at recombinant GABAC receptors. These inhibitory effects of quercetin and quercetin-
glycosides on GABA-induced inward current were noncompetitive and membrane voltage-
insensitive, indicating that quercetin and its glycosides regulate GABAC receptor channel 
activity through interaction with a different site from that of GABA [216]. This study also 
provides evidence that the number of carbohydrate attached to quercetin might play an 
important role in the regulation of GABAC receptor channel activity. On the contrary, 6-
methoxyflavanone and 6-methoxyflavone were inactive as modulators at human recombinant 
receptors containing ρ1 subunits [210].  
Interestingly, menthol, a naturally occurring compound in the essential oil of mint 
leaves, also act as a positive allosteric modulator of recombinant GABAA receptors. In 
particular, menthol (150-750 μM) produced a concentration-dependent prolongation of 
spontaneous GABAA receptor-mediated inhibitory postsynaptic currents in the periaqueductal 
grey (PAG) neurons, although menthol actions were unaffected by the benzodiazepine 
antagonist flumazenil. Menthol also enhanced a tonic current, which was sensitive to the 
GABAA receptor antagonists picrotoxin and bicuculline, but unaffected by gabazine and 
GABAC receptor antagonist (1,2,5,6-tetrahydropyridine-4-yl)-methyl-phosphonic acid 
(TPMPA). In addition, menthol potentiated currents induced by the extrasynaptic GABAA 
receptor agonist THIP, altogether indicating that menthol positively modulates both synaptic 
and extrasynaptic populations of GABAA receptors in native PAG neurons [217].  
 
GABAC receptors 
 
GABAC receptors are considered as a specific subtype of GABAA receptors due to 
their structural homology, although they differ from GABAA receptors by biochemical, 
pharmacological and physiological properties [218-220]. They are predominantly expressed 
in the retina where play a unique functional role in retinal signal processing, but are also 
expressed throughout brain and in periphery [221,222]. GABAC receptors are involved in 
numerous processes across the CNS, including vision, olfactory senses, sleep, memory and 
cognitive functions, hormone secretion and pain perception, with promising potential for the 
treatment of myopia, sleep disorders, memory and learning enhancement, and fear and 
anxiety-related disorders [222,223]. Although understanding of the role of GABAC receptors 
and processes triggered by ligand–receptor interactions in neurons are still limited because of 
the lack of adequate pharmacological tools, some progress has been made following synthesis 
and pharmacological evaluation of the selective fluorescent and biotinylated probes for ρ1 
GABAC receptors that hopefully will bring new knowledge regarding the binding site and 
GABAC receptors flexibility, and be useful tools for localizing, visualizing, and studying the 
physiopathological processes of GABAC receptors [224].  
In mammals, there are three isoforms of ρ subunits (ρ1-ρ3) that form homooligomeric 
(formed by ρ1, ρ2 or ρ3 isoform) or pseudoheteromeric (made up of a combination of ρ1 and 
ρ2 isoforms or ρ2 and ρ3 isoforms) GABAC receptor pentamers [220,224]. In humans, only 
two isoforms are expressed: ρ1 and ρ2.  
 GABAC receptors are sensitive neither to bicuculline (characteristic ligand of GABAA 
receptors) nor to baclofen (characteristic ligand of GABAB receptors) [222,225]. They are 
more sensitive to GABA than GABAA receptors, and at least three GABA molecules are 
required to activate the GABAC receptor [222]. When activated, they have a smaller chloride 
conductance, longer channel opening time and desensitize less readily in the presence of 
GABA then GABAA receptors [218]. Benzodiazepines and barbiturates do not modulate 
GABAC receptors [218]. Neuroactive steroids may modulate GABA-induced current at 
GABAC receptors, in particular at ρ1 receptor channels, in both positive and negative manner, 
although the modulation occurs with relatively high concentrations of neuroactive steroids 
and is more prominent in the presence of low concentrations of GABA [226]. Characteristic 
agonists of GABAC receptors are cis enantiomer of 4-aminocrotonic acid (CACA) and (+)cis-
2-aminomethylcyclopropane carboxylic acid ((+)-CAMP) [218]. Furthermore, GABAC 
receptors are much less sensitive to GABAA receptor antagonist gabazine, but can be 
selectively antagonized by (1,2,5,6-tetrahydropyridine-4-yl)-methyl-phosphinic acid 
(TPMPA), 3-aminopropyl(methyl) phosphinic acid (3-APMPA), and 3-
aminopropylphosphonic acid (3-APA), indicating that agonist/antagonist binding pockets of 
GABAA and GABAC receptors are not the same [220,227,228]. Compound imidazole-4-acetic 
acid exhibits a ρ subunit-dependent pharmacological profile: at ρ1 and ρ3 receptors acts as a 
potent antagonist, while at ρ2 receptors as a potent partial agonist [222]. 
N-terminal half of the ρ subunits has been shown to mediate formation of homo- and 
heterooligomeric GABAC receptors, and specific sequence within the N-terminus of the ρ1 
subunit involved in the assembly process has been determined [229]. Furthermore, several 
key structural elements that determine specific pharmacological response of GABAC 
receptors have been found [228]. Namely, mutational studies, including those directed toward 
N-terminal domain and transmembrane domain TM4, have revealed residues that change 
sensitivity to agonists or make GABAC complex inactive, and contribute to the binding pocket 
determining properties of GABA binding [221,230,231]. Thus, Tyr102 at ρ1 subunit was 
identified as part of GABA binding domain, and probably the important residue for coupling 
agonist binding to channel opening [232]. Barbiturate sensitivity was imparted by mutation of 
Trp328 at ρ1 subunit, located within the transmembrane domain TM3. It also seems that this 
residue plays an important role in agonist-dependent activation, suggesting a functional 
interconnection between the GABA and pentobarbital activation domains [233]. GABAC 
receptors that contain ρ2 subunit exhibit decreased sensitivity to picrotoxin [234]. On ρ1 
receptor it is shown that the mechanism of picrotoxin effects is compatible with an allosteric 
inhibition and receptor activation was a prerequisite for antagonism [235]. Difference in 
picrotoxin sensitivity of ρ1 and ρ2 homo-oligomers is determined by a single residue. 
Interestingly, it was found that this amino acid in the putative channel domain (TM2) of 
GABA ρ1 receptors influences picrotoxin sensitivity, and also meditates agonist binding by 
an allosteric mechanism [236].   
 
GABAB receptors 
 
Metabotropic GABAB receptors are G-protein coupled receptors that mediate slow and 
prolonged inhibitory neurotransmission in the brain [237]. They are widely expressed and 
distributed in the CNS, although GABAA sites generally outnumber GABAB sites [238]. 
GABAB receptors differ from GABAA receptors by their structural and functional properties, 
but also exhibit numerous pharmacological effects, including central muscle relaxation, 
epileptogenesis, suppression of drug craving, antinociception, cognitive impairment and 
inhibition of hormone release [12,239]. 
GABAB receptors can be located presynaptically and postsynaptically. Stimulation of 
presynaptic GABAB receptors decreases conductance of calcium ions via voltage-gated 
calcium channels. Consequently, activation of presynaptic GABAB autoreceptors induces 
inhibition of GABA release, while presynaptic GABAB heteroreceptors suppress release of 
other neurotransmitters and bioactive peptides. Depending on whether synaptic terminal 
releases an inhibitory or excitatory neurotransmitter, presynaptic GABAB receptors will 
facilitate or suppress neuronal excitability thus playing important role in tuning various 
synapses [12,240,241]. On the other hand, postsynaptic GABAB receptors are coupled via G-
proteins to inwardly rectifying potassium channels and underlie slow inhibitory postsynaptic 
currents. Postsynaptic GABAB receptors stimulate efflux of potassium ions that 
hyperpolarizes neuronal membrane and shunts excitatory currents. As presynaptic and 
postsynaptic GABAB receptors are dominantly located at extrasynaptic sites, their activation 
requires patterns of presynaptic activity that ends in simultaneous GABA spillover from 
neighbouring synapses and elevations of ambient GABA, as it occurs during epileptic 
seizures. Furthermore, the association of GABAB receptors with glutamatergic synapses 
suggests their important role in the modulation of glutamatergic neurotransmission 
[240,242,243].  
The GABAB receptor was the first heteromeric G-protein coupled receptor identified. It 
functions as an obligatory heterodimer assembly: both GABAB1 and GABAB2 subunits are 
necessary to form a functional GABAB receptor, and neither of these subunits is functional on 
its own [244] (Kaupmann et al. 1998). Soon after the cloning of both subunits, it was 
demonstrated that GABAB2 is required for GABAB1 to reach the cell surface by masking an 
endoplasmic reticulum retention signal of GABAB1 [245]. However, GABAB2 is not only 
required for the correct trafficking of GABAB1, but also for the proper functioning of the 
receptor. In particular, GABAB1 is involved in ligand recognition via its N-terminal 
extracellular domain and it binds GABA [246]. Although GABAB2 subunit does not constitute 
a binding site for any natural GABAB ligand [247], it enhances agonist affinity [248], and is 
required for receptor activation. In addition, GABAB2 subunit is responsible for G-protein 
coupling [249].  
There are two physiologically significant isoforms of GABAB1 subunit, GABAB1a and 
GABAB1b that differ in N-terminal region. Expression of these two subunits is 
developmentally regulated at the transcription level. They are transcribed from the same gene 
after activation of alternative promoters [250]. Accordingly, there are two major subtypes of 
GABAB receptor, one formed from GABAB2 and GABAB1a subunits, and the other formed 
from GABAB2 and GABAB1b subunits [240].  
GABAB1 and GABAB2 subunits are structurally homologous and both possess two main 
domains: a heptahelical membrane domain that is responsible for recognition and activation 
of G-proteins (HD domain), and a large extracellular “Venus flytrap” domain (VFT domain) 
involved in ligand binding. Both domains oscillate between different conformational states, 
and these allosteric transitions are essential for receptor function and offer numerous 
possibilities for the allosteric regulation of receptor activity. GABA and other agonists bind 
exclusively at the VFT domain of the GABAB1 subunit, but VFT domain of the GABAB2 
subunit is necessary for the activation of whole receptor. On the other hand, GABAB2 HD 
contains molecular determinants required for G-protein coupling, and by trans-activation 
mechanism, binding of GABA at VFT domain of GABAB1 subunit lead to activation of HD 
domain of GABAB2 subunit [251-253]. However, the HD of GABAB1 improves coupling 
efficacy. Conversely, although GABAB1 extracellular domain is sufficient to bind GABAB 
ligands, the extracellular domain of GABAB2 increases the agonist affinity on GABAB1, and is 
necessary for agonist activation of the receptor. Altogether, this indicates that multiple 
allosteric interactions between the two subunits are required for wild-type functioning of the 
GABAB receptor [251]. 
Geng et al. [254] presented the crystal structures of heterodimeric GABAB complex 
consisting of extracellular VFT domains of GABAB1 and GABAB2 subunits in the apo, 
agonist-bound and antagonist-bound forms. The apo and antagonist-bound structures 
represent the resting state of the receptor; while the agonist-bound complex corresponds to the 
active state. They found that both subunits adopt an open conformation at rest, but only 
GABAB1 VFT closes on agonist-induced receptor activation. Furthermore, they revealed a 
unique activation mechanism for GABAB receptor that involves the formation of a novel 
heterodimer interface between subunits. 
GABAB receptors are not modulated by benzodiazepines, barbiturates, or steroids, and 
are not sensitive to bicuculline [218,225]. Characteristic agonists of GABAB receptors are 
baclofen, a lipophilic derivative of GABA, and 3-aminopropylphosponous acid (3-APPA; 
CGP27492), while saclofen, phaclofen and 2-hydroxysaclofen act as antagonists of GABAB 
receptors [12]. Baclofen was introduced to the market in 1972 and is used to treat spasticity 
and skeletal muscle rigidity in patients with spinal cord injury, multiple sclerosis, 
amyotrophic lateral sclerosis, and cerebral palsy. However, although GABAB agonists showed 
promising therapeutic effects in a whole range of other indications, they exhibit numerous 
side effects, including sedation, tolerance, and muscle relaxation [237,256].  
 
Conclusions 
GABAA receptors mediate most of the fast synaptic inhibition in the mammalian brain 
and are targeted by many clinically important drugs. They are subject to modulation at a 
variety of allosteric sites, with pharmacology dependent on receptor subunit combination. In 
addition to GABA, naturally occurring steroids can potently and specifically enhance GABAA 
receptor function in a direct manner, and consequently exert anxiolytic, analgesic, 
anticonvulsant, sedative, hypnotic and anesthetic properties. GABAA receptors are thus 
important for function and plasticity of the CNS. Analysis of the specific roles of GABAAR 
subtypes reveals their involvement in the pathophysiology of major CNS disorders, and opens 
novel perspectives for therapeutic intervention. Further pharmacological studies will 
contribute to more complete understanding of numerous interactions between various ligands 
and their binding sites on GABA receptors that might improve current pharmacological 
approach in treating various diseases. 
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